The clinical study on immunotherapy for advanced renal cell carcinoma =Combination therapy of natural IFN-alfa and meloxicam against metastatic renal cell crcinoma=

The clinical study on immunotherapy for advanced renal cell carcinoma =Combination therapy of natural IFN-alfa and meloxicam against metastatic renal cell crcinoma= - Combination therapy with meloxicam, a COX-2 inhibitor, and interferon alfa for metastatic renal cell carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001772

Enrollment

Registered

2009-03-13

Start date

2004-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic renal cell carcinoma

Interventions

the subcutaneous injection of natural IFN-alfa at 3 mllion unit (MU) or 5 MU three times weekly plus oral administration of meloxicam (Morbic) at 10 mg once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patients with untreated renal carcinoma who were diagnosed from the results of imaging or pathological studies 2.patients who had measurable lesions according to the Response Evaluation Criteria in Soild Tumors (RECIST) 3. PS 0-2 (ECOG) 4. Patients with the absence of cardiac, hepatic, renal, or bone marrow dysfunction 5. Patients with expected survival for 3 months or longer 6. written informed consent from the patient

Exclusion criteria

Exclusion criteria: 1. prior immunotherapy 2. Brain metastasis 3. Bone metastasis alone 4. active double cancers 5. Liver cirrhosis 6. uncontolled DM 7. Depression

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
time to progression overall survival adverse events	—

Countries

Japan

Contacts

Public ContactNobuo Shinohara

Hokkaido University Graduate School of Medicine Department of renal and genitourinary surgery

nobuo-s@med.hokudai.ac.jp011-706-5965

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026